Peregrine Pharmaceuticals reported $4.34M in EBITDA for its second fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Ebitda Change
Agenus AGEN:US $ -43.28M 8.94M
Amgen AMGN:US $ 3004M 337M
AstraZeneca AZN:LN 292568.43M 24571.33M
Bristol Myers Squibb BMY:US $ 5780M 8M
Celldex Therapeutics CLDX:US $ -20.66M 1.79M
Chemocentryx CCXI:US $ -30.55M 6.67M
Eli Lilly And LLY:US $ 1999.4M 1006.2M
GlaxoSmithKline GSK:LN 244700M 1400M
Karyopharm Therapeutics KPTI:US $ -42759000 8.35M
Macrogenics MGNX:US $ -38931000 24.79M
Mannkind MNKD:US $ -23.55M 1.63M
Minerva Neurosciences NERV:US $ -6.96M 1.02M
Novartis NOVN:VX SF 4660M 108M
Peregrine Pharmaceuticals PPHM:US $ 4.34M 1.85M
Repligen RGEN:US $ 71.08M 1.53M
Xencor XNCR:US $ -25.78M 54.42M